Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Significant Increase in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,230,000 shares, an increase of 58.5% from the October 15th total of 776,000 shares. Approximately 3.8% of the company’s shares are sold short. Based on an average daily volume of 618,200 shares, the days-to-cover ratio is presently 2.0 days.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $1.77 on Friday. The company has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.88. The company has a market cap of $78.88 million, a price-to-earnings ratio of -1.16 and a beta of 0.41. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 52 week low of $1.66 and a 52 week high of $8.19.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently modified their holdings of the business. PFM Health Sciences LP grew its stake in shares of Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after acquiring an additional 157,673 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Werewolf Therapeutics in the first quarter valued at $10,922,000. Millennium Management LLC boosted its stake in Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after acquiring an additional 544,881 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after buying an additional 233,909 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after buying an additional 52,528 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.